King Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?
KING PHARMS has twenty-seven approved drugs.
There is one US patent protecting KING PHARMS drugs.
There are two patent family members on KING PHARMS drugs in two countries and nine supplementary protection certificates in six countries.
Summary for King Pharms
| International Patents: | 2 |
| US Patents: | 1 |
| Tradenames: | 25 |
| Ingredients: | 23 |
| NDAs: | 27 |
Drugs and US Patents for King Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| King Pharms Llc | TAPAZOLE | methimazole | TABLET;ORAL | 040320-001 | Mar 31, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| King Pharms Llc | INTAL | cromolyn sodium | SOLUTION;INHALATION | 018596-001 | May 28, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| King Pharms | CROMOPTIC | cromolyn sodium | SOLUTION/DROPS;OPHTHALMIC | 075088-001 | Apr 27, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| King Pharms Llc | BICILLIN L-A | penicillin g benzathine | INJECTABLE;INJECTION | 050141-001 | Approved Prior to Jan 1, 1982 | BC | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| King Pharms | PROCANBID | procainamide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020545-001 | Jan 31, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-006 | May 25, 2001 | AB1,AB3 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for King Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-006 | May 25, 2001 | 7,067,148 | ⤷ Sign Up |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-005 | May 25, 2001 | 7,101,569 | ⤷ Sign Up |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-002 | Jan 28, 1991 | 7,368,469 | ⤷ Sign Up |
| King Pharms Llc | INTAL | cromolyn sodium | SOLUTION;INHALATION | 018596-001 | May 28, 1982 | 3,777,033 | ⤷ Sign Up |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-002 | May 25, 2001 | 7,067,148 | ⤷ Sign Up |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-007 | May 25, 2001 | 6,555,581 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for KING PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 30 mg, 60 mg, 90 mg and 120 mg | ➤ Subscribe | 2007-06-04 |
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2004-11-04 |
| ➤ Subscribe | Extended-release Capsules | 45 mg and 75 mg | ➤ Subscribe | 2009-07-30 |
International Patents for King Pharms Drugs
Supplementary Protection Certificates for King Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1539166 | 2013C/064 | Belgium | ⤷ Sign Up | PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626 |
| 0350733 | SPC/GB03/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313 |
| 1539166 | 2013/055 | Ireland | ⤷ Sign Up | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| 0265685 | 99C0001 | Belgium | ⤷ Sign Up | PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919 |
| 1539166 | 92323 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| 1539166 | 13C0062 | France | ⤷ Sign Up | PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
